Targeting the PI3K/Akt/mTOR pathways is a promising strategy in cancer, and possible in VHL treatment due to their central role in tumor biology, potential to overcome resistance, and ability to enhance the effectiveness of existing therapies [123]. Here, AKT1 is linked to neoplasm.